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1. INTRODUCTION 
 
1.1 Schwann cells and their role in the peripheral nervous system 
 
The peripheral nervous system (PNS) includes the cranial nerves, spinal nerves, peripheral 
nerves and neuromuscular junctions. Nerve fibers (axons) of these nerves extend far from the clusters 
of neuron cell bodies (ganglions) to conduct information towards and away from the central nervous 
system (CNS). They are bound together by sheaths of connective tissue, with the endoneurium 
surrounding individual fibers, perineurium binding fibers into fascicles and epineurium binding 
fascicles into nerves [1].  
 
Figure 1 Structure of an adult peripheral nerve. 
Nerve fibers, or axons, are surrounded with a myelin sheath and are bound together with a layer of connective 
tissue, called the endoneurium. Fibers are further bound into fascicles and surrounded by the perineurium. Many 
fascicles brought together and surrounded by the epineurium make up an adult peripheral nerve. Figure adapted 
from [1]. 
 
The sheath adjacent to the neuron membrane (neurilemma) is the endoneurium (Figure 1). It 
contains blood capillaries that provide nutrients and oxygen, as well as transport macrophages for 
nerve protection. The endoneurium also contains cells that are unique for the PNS, Schwann cells 
(SCs). The SC membrane forms a multilayered insulating lipid sheath (myelin sheath) enwrapping the 
axon in segments (Figure 2). Each segment belongs to a single SC and is separated by non-myelinated 
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spots (nodes of Ranvier, Figure 2). These spots make the border between adjacent SCs and allow the 
signal to be propagated in a series of jumps from node to node. The myelin sheath prevents signal loss 
and reduces any additional metabolic requirements for neural activity [1]. 
 
Figure 2 Schwann cells surround the axon and form the myelin sheath. 
The Schwann cell membrane forms a myelin sheath which enwraps the axon in segments. Each segment belongs 
to a single Schwann cell and is separated by non-myelinated spots (nodes of Ranvier). These spots make the 
border between adjacent Schwann cells and allow a continuous propagation of the nerve signal. Figure adapted 
from https://shwannomawebpaper.wordpress.com/ on 11.08.2016. 
 
First described by physiologist Theodor Schwann [2], the Schwann cells, glia of the PNS, are 
derived from the neural crest and migrate together with nerve cells to form peripheral nerves [3]. They 
have various roles in the PNS, such as being involved in nerve development and regeneration, or 
cleaning up of neuronal debris [4]. Furthermore, they provide trophic factors for neurons [5], modulate 
neuromuscular synaptic activity and can recruit antigen-presenting cells to the site of injury [6].  
SC precursor cells originate from the neural crest and, along with generation of immature SCs, 
can develop into melanoblasts [7], parasympathetic neurons [8] and endoneurial fibroblasts, which 
form the connective tissue that appears in nerves [9]. Survival of SC precursor cells is essentially 
dependent on neuronal signals [10, 11], while immature SCs are less neuron-dependent and can rely 
on the secretion of their own autocrine signals [10, 11]. Further immature SC proliferation and 
differentiation, though, remains neuron-dependent to a great extent [12].  
Immature SCs develop into myelinating or non-myelinating cells (Figure 3) that retain their 
phenotypic plasticity and can switch back to former developmental stages in response to nerve injury 
[13], which is a characteristic that contributes to the striking regenerative properties of the PNS.  
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Figure 3 Four stages of Schwann cell development. 
Schwann cell precursor cells originate from the neural crest and, while developing towards the Schwann cell 
lineage, can form myelinating or non-myelinating Schwann cells, which retain their phenotypic plasticity and 
can switch back to former developmental stages in response to nerve injury. Figure adapted from [14]. 
 
Myelinating SCs remain consistently dependent on neurons and, even though they have the 
ability to survive without axonal contact in response to nerve damage, after longer periods of no 
axonal contact, most of them eventually die [15]. Similarly, neurons need the presence of SCs for 
normal branching and target interactions in early development [12, 16], as well as their neurotrophic 
support for cell differentiation [17] and survival in later stages of development. The role of SCs in 
nerve cell differentiation makes the pronounced interdependence between these two cell types 
especially interesting in regards to deciphering the biology of tumors originating from the sympatho-
adrenal lineage of the PNS, neuroblastomas.  
 
1.2 Neuroblastoma 
 
Neuroblastoma (NB) is a solid tumor originating from trunk neural crest-derived neuroblasts that 
most commonly affects infants and children. Tumors most frequently arise in the adrenal glands or 
ganglia but, in some cases, also in other sites like the abdomen or chest. The biology of NB differs 
greatly among different types of tumors and the characteristics are highly dependent on the age of the 
patient, as well as stage and genetic profile of the tumor [18]. Manifestations can range from 
spontaneously regressing to very aggressive metastasizing forms and several genomic alterations, 
which can be linked to the different patterns of clinical behavior, have so far been identified. 
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Tumors can be divided into 2 major types [18]:  
1. Type 1 NBs are characteristic for very young patients and show numerical chromosome 
abnormalities (NCAs) (near triploidy) (Figure 4), without additional segmental 
chromosome abnormalities (SCAs) [19, 20]. SCAs in general go together with diploidy or 
tetraploidy [21], although can sometimes occur in near-triploid NBs, thereby affecting the 
prognostic impact of these tumors [20]. Type 1 NBs show high expression of the TrkA 
(tropomyosin receptor kinase) neurotrophin receptor and have the ability to undergo 
differentiation in the presence of normal SCs and its ligand NGF (nerve growth factor) in 
the microenvironment, or spontaneous regression (apoptosis) in the absence of NGF [22], 
frequently leading to a favorable clinical outcome for patients (in both cases). 
 
2. Type 2 tumors (Figure 4) are associated with patients of older age and an unfavorable 
advanced tumor stage that is linked to frequent SCAs - like an unbalanced gain of 
chromosome arm 17q, which is a frequent event in both subtypes (2A, 2B). Subtype 2A 
often has additional segmental losses of chromosome arms 3p, 4p and/or 11q and gain of 
chromosome 7. Subtype 2B is characterized by MYCN amplification, frequently 
associated with 1p deletion [23]. Type 2 tumors also show high expression of the TrkB 
neurotrophin receptor and its ligand BDNF (brain-derived neurotrophic factor). Activation 
of the TrkB-BDNF autocrine signaling pathway leads to invasion, metastasis, 
angiogenesis and drug resistance [24].  
 
Figure 4 The major genomic alterations involved in neuroblastoma development. 
Type 1 neuroblastomas are tumors with a favorable clinical outcome, which have the ability to undergo 
differentiation in the presence of NGF in the microenvironment, or apoptosis in its absence. Type 2 
neuroblastomas are clinically unfavorable and linked to frequent SCAs, with the subtype 2B tumors being the 
most rapidly progressive ones. NCAs: numerical chromosomal abnormalities; SCAs: segmental chromosomal 
abnormalities; NGF: nerve growth factor; TrkA/B: tropomyosin receptor kinase A/B. Figure adapted from [18]. 
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Although aggressive forms of neuroblastoma frequently relapse and lead to death of patients, 
NB is considered as one of the cancers with the highest probability to undergo spontaneous regression 
[25]. This phenomenon contributed to classification of a subset of infants currently designated as L1, 
L2 and MS stages according to the International Neuroblastoma Risk Group (INRG) staging system 
[26]. MS stage patients present small primary tumors, less than 10% of bone marrow involvement, are 
less than 18 months of age at diagnosis and the tumors lack MYCN amplification. Additionally, the 
tumors of these patients were shown to be mostly near triploid with whole chromosome gains [27]. 
Fully mature types of tumors, so-called ganglioneuroma, are composed of few ganglionic cells 
(differentiated neuroblasts) that are surrounded by a dense SC stroma. There are also intermediate 
types called ganglioneuroblastomas, in which the extent of the SC stroma varies, which is directly 
correlated with the level of tumor maturation, as well as to a favorable prognosis [28, 29]. The finding 
that the SCs in these tumors do not originate from NB cells was first described by Ambros et al. [22]. 
1.3 Previous research on the Schwann cell – neuroblastoma interaction in 
fully mature neuroblastomas  
 
SCs originate from a pluripotent neural crest cell (Figure 5) and thus share a common 
progenitor with neuroblasts, which is why they were for long considered to be of neoplastic origin. 
This was based on two observations: first, in ganglioneuroma and ganglioneuroblastoma, SCs 
frequently make up the majority of the tumor mass and second, in neuroblastoma in vitro cell cultures, 
besides the neuronal-type cells,  an additional fibroblast-like cell type, was found and considered to 
represent SCs [30, 31]. However, Ambros et al. showed that, in MYCN amplified NB cell lines, these 
fibroblast cells with flat morphology are revertants (senescent cells), and not SCs [32, 33], proving 
that these previous assumptions were misconceptions. 
 
Figure 5 Immunofluoresence-stained cryosection of a fully mature neuroblastoma (ganglioneuroma). 
Cells positive for the differentiation marker NF200 are shown in red and cells positive for the Schwann cell 
marker S100 in green. Cell nuclei labeled with DAPI-stain are shown as blue. Nuclei negative for either of the 
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markers belong to fibroblasts or blood vessels. The predominance of stromal Schwann cells in the tumor is 
clearly visible. Image kindly provided by Tamara Weiss, CCRI, Vienna. DAPI: 4', 6-diamidino-2-phenylindole; 
CCRI: Children’s Cancer Research Institute. 
 
As the physiologic properties and functions of SCs became clearer in the early 1990s, the 
interest for their role in tumor maturation arose, and several groups aimed to decipher this matter. 
Nonetheless, this was challenging at that time, since cells in ganglioneuromas do not proliferate and 
conventional cytogenetic methods could not be used. Ambros et al. used in situ hybridization and 
immunohistochemical analysis on paraffin sections, together with flow cytometry, to measure DNA 
content and detect numerical and segmental chromosomal aberrations [22]. They demonstrated that 
SCs in ganglioneuromas have a diploid DNA content and a disomic in situ hybridization pattern, 
whereas the ganglionic cells showed clonal aneuploidy (e.g. trisomy) [22], suggesting that SCs in 
ganglioneuromas and ganglioneuroblastomas are cells of non-neoplastic origin that invade the tumor 
and form a specialized tumor stroma. 
Based on these data, they proposed a model (Figure 6) in which undifferentiated aneuploid NB 
cells secrete chemotactic factors that recruit SCs. The neuron-associated mitogens provoke SC 
proliferation and migration, and the SCs migrate into the tumor using neuritic processes for their 
guidance. Further stimulated by the NB cells, once in tumor proximity, the SCs secrete neurotrophins, 
such as NGF, BDNF and CNTF (ciliary neurotrophic factor), that act on NB cells and inhibit NB cell 
proliferation, induce cell differentiation and/or apoptosis, leading to a fully mature tumor [22]. 
 
Figure 6 Proposed model of neuroblastoma maturation.  
Favourable neuroblastoma cells have the ability to attract Schwann cells by secretion of Schwann cell-recruiting 
chemotactic factors. Once in tumor proximity, the Schwann cells secrete neuritogens that inhibit neuroblastoma 
cell proliferation, induce cell differentiation and/or apoptosis, in that way stimulating the formation of a fully 
mature neuroblastoma. Figure adapted from [22]. 
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The proposed model is supported by the fact that aggressive MYCN non-amplified types of 
tumors can present with a SC stroma after chemotherapy [34], indicating the proposed ability of tumor 
cells to recruit SCs. Secondly, the SCs present in differentiating tumors can frequently be found at the 
outer portion of the tumor and are not intermingled with NB cells in a way that would be expected if 
they arose from the same cells as tumor cells [22]. Moreover, SCs occurring in fully mature NBs, 
ganglioneuromas, cannot be distinguished from SCs present in the PNS in their spatial organization 
[22]. These SCs have also been shown to have only limited morphological similarities to neoplastic 
SC versions that form schwannomas [35]. Another important fact is the high expression of high and 
low affinity NGF receptors, p140trkA and p75NGFR, respectively, in aneuploid forms of NB [36, 37]. The 
ligand for these receptors, NGF, is essential for inducing differentiation of sympathetic neuronal cells 
and, since SCs are a valuable source of NGF, they could, according to the proposed model [22], 
trigger the maturation process in NB.  
Soluble SC-secreted factors that mediate the SC-NB cross-talk and that could influence 
neuroblastoma maturation, have so far been investigated by several groups. SPARC (secreted protein 
acidic and cysteine rich) is an example of a factor that was identified as one of the SC-derived 
inhibitors controlling neuroblastoma tumor angiogenesis [38]. Another example is PEDF (pigment 
epithelium-derived factor), that was shown to induce tumor cell differentiation in vitro. Its 
recombinant form was shown to have the same effects in vitro and in vivo [39]. However, the analysis 
of the SC secretory profile has so far been restricted to single candidate factors and a comprehensive 
analysis has not yet been performed. 
 
1.4 Preliminary data on Schwann cell - neuroblastoma in vitro co-
cultivation  
 
The published [35] and new preliminary data of the Tumor Biology group at the Children’s 
Cancer Research Institute (CCRI), Vienna, on in vitro co-cultivation experiments of primary human 
peripheral nerve-derived SCs and NB cell lines with different genetic backgrounds, derived from high-
risk NB patients (representing type 2 tumors, Figure 4), have confirmed a tumor-inhibiting and 
differentiation-inducing effect of SCs on NB cells, as examined by flow cytometry and 
immunocytology manuscript in preparation. These experiments also demonstrated induction of 
apoptosis according to TUNEL assays, all together proving that the SC-NB interactions in the tumor 
can be replicated in vitro. Furthermore, SC-NB transwell cultures that prohibit direct cell-cell contact, 
while media and proteins diffuse freely through the microporous membrane of the insert, demonstrated 
that secreted factors are involved, since the effects were similar as with direct co-cultivations 
(manuscript in preparation). 
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1.5 Hypothesis and aim of study  
 
Based on the hypothesis that SCs secrete factors that have an anti-proliferative and 
differentiation-inducing effect on NB cells, the aim of this master thesis was to investigate the 
mechanism of this process by identifying the factors involved, and defining the concentration and 
combination needed to provoke inhibition of cell proliferation and induction of cell differentiation of 
neuroblastoma cells. 
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2 MATERIALS AND METHODS  
 
2.1 Cell lines and cell culture 
 
Cultivation of NB cell lines was performed using αMEM complete medium (αMEM+): 
αMEM (Gibco, Austria) containing 10% fetal bovine serum (FBS; Sigma-Aldrich, Austria), 25 mM 
HEPES buffer solution (Pan Biotech, Germany), 1 mM sodium pyruvate (Na-pyruvate, Pan Biotech, 
Germany) and 1% Penicillin/Streptomycin (P/S, Pan Biotech, Germany). The cell lines used and their 
genetic characteristics are listed in Table 1. 
Table 1 Characteristics of neuroblastoma cell lines used in in vitro cultivation experiments. 
 
 
S
T
A
–
N
B
–
1
0
 
S
T
A
-N
B
-6
 
C
L
B
-M
a
 
IM
R
5
 
S
H
S
Y
5
Y
 
INSS stage 3 3 4 n.a. 4 
Patient outcome DOD CR n.a. n.a. DOD 
MYCN amplification Yes 
dmin 
No Yes 
dmin 
Yes 
HSR 
No 
Ploidy di-/tetra-ploid aneuploid diploid n.a. diploid 
17q gain Yes Yes Yes n.a. Yes 
1p loss Yes Yes Yes Yes No 
Reference [33, 40] [33, 40] [41] [42] [43] 
INSS: International neuroblastoma staging system; n. a.: not available; DOD: dead of disease; CR: complete 
remission; dmin: double minute chromosomes; HSR homogenously staining region; wcUPD: whole 
chromosome uniparental disomy. 
 
All cell lines were previously derived from tumor tissue or bone marrow samples from INSS 
stage 3 or 4, i.e. high-risk NB patients. Tumor tissue and bone marrow samples were provided by the 
St. Anna Children’s Hospital, Vienna. Informed consent was obtained for the collection and research 
use of human tumor tissue and bone marrow samples according to the guidelines of the Council for 
International Organizations of Medical Sciences and the World Health Organization and was approved 
by the local ethics committees of the Medical University of Vienna and the St. Anna Children’s 
Hospital.  
The cells were stored in liquid nitrogen, or at -80 °C in an FBS solution with 10% 
Dimethylsulfoxid (DMSO, Roth, Germany). When needed, cells were thawed, αMEM+ was added 
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and they were kept in a CO2-incubator (5% CO2) at 37 °C. Cells were sub-cultured after reaching 80% 
confluency. Media was removed, cells were rinsed with 1x Dulbecco’s Phosphate-Buffered Saline (D-
PBS, PAN Biotech, Germany) and detached by adding 1.5 mL of Accutasse (cell detachment solution, 
PAN Biotech, Germany) for a 75 cm2 culture flask (T75), or 700 μL for a 25 cm2 sized culture flask 
(T25), respectively, for 2-3 minutes. αMEM+ media was added in a volume of 8 mL, the cell 
suspension was transferred to a 15 mL tube and centrifuged at 1100 rpm for 5 minutes at 4 °C (all cell 
detachment, harvesting and splitting procedures mentioned throughout the text have been performed in 
the same manner, if not otherwise stated). The pellet was resuspended in αMEM+ medium, in a 
volume depending on the splitting ratio (i.e. for a 1:2 splitting, 1 mL of αMEM+ medium was used) 
and the cells were further cultured in a total volume of 12 mL media for a T75 culture flask or 7 mL 
media for a T25 flask, including 1/3 of conditioned media (media conditioned by the NB cell line from 
the previous passage) (e.g.. for a T75 flask, 8 mL of fresh and 4 mL of conditioned media was 
combined). 
 
2.2 Isolation of human Schwann cells from peripheral nerve tissue and 
their co-cultivation with the STA-NB-6 cell line 
 
2.2.1 Isolation of nerve fascicles  
 
Peripheral nerve tissue samples were provided by the Department of Orthopedic Surgery or 
the Department of Plastic and Reconstructive Surgery at the Vienna General Hospital. Informed 
consent was obtained for the collection and research use of human peripheral nerve tissues according 
to the guidelines of the Council for International Organizations of Medical Sciences and the World 
Health Organization and was approved by the local ethics committees of the Medical University of 
Vienna and the St. Anna Children’s Hospital. Human peripheral nerves were collected during 
reconstructive surgery, amputations or organ donations of male and female patients between 16 and 70 
years of age. Nerves were stored in sterile saline for 1–3 h until further processing. 
The peripheral nerve was washed one time with cold 1x D-PBS, transferred into an autoclaved 
glass dish and covered with αMEM+ medium (Figure 7a). The nerve was cut with the use of a lancet 
into pieces of around 3 cm in length and any extra connective or adipose tissue was thereby removed. 
Nerve fascicles were pulled out of the epineurium using forceps and separated from the remaining 
tissue into a different autoclaved glass dish containing αMEM+ medium (Figure 7b). The fascicles 
were further cut into 5 mm pieces. The isolated cut fascicles were equally distributed into wells of a 6-
well plate (Figure 7c) and incubated overnight in 2 mL of digestion solution (αMEM+, 0.125% 
collagenase Type IV (GIBCO), 1.25 U/ml Dispase II (SIGMA) and 3 mM CaCl) at 37 °C [44]. 
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Figure 7 Schwann cell isolation procedure. 
a) Peripheral nerve tissue covered with αMEM+; b) pulled nerve fascicles covered with αMEM+; c) nerve 
fascicles in 2 mL digestion solution. 
 
2.2.2 Coating of culture dishes 
 
Surfaces of culture dishes were coated with 0.01% Poly-L-lysine Hydrobromide solution 
(PLL, Sigma-Aldrich, Austria), which was added in a volume of 1 mL to each well of a 6-well plate 
and distributed equally. The plate was shaken every minute to maintain the equal distribution of the 
solution. After 10 min, the wells were gently washed two times with ddH20 and the plate was left to 
dry for 2 h at room temperature (RT) [44]. The plate was then incubated at 37 °C with 1 mL of 
Laminin solution (6 μg/mL in 1x D-PBS, Engelbreth-Holm-Swarm murine sarcoma, Sigma-Aldrich, 
Austria) and washed the following day two times with 1x D-PBS, after which 1 mL of Schwann cell 
expansion media (SCEM; MEMα, 1% P/S, 2% FBS, 1 mM sodium pyruvate, 25 mM HEPES, 10 
ng/ml human FGF basic, 10 ng/ml human Heregulinβ1, 5 ng/ml human PDGF-AA (all PeproTech), 
0.5% N2 supplement (GIBCO) and 2 µM forskolin (SIGMA) [44]) was added to each well. The same 
procedure was used for coating of transwell inserts. 
2.2.3 Schwann cell seeding  
 
After overnight incubation, residual tissue was mechanically resuspended with a pipette to 
ensure homogeneity of the solution. After the addition of αMEM+, digested tissue was transferred into 
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15 mL tubes and centrifuged at 1000 rpm, RT. The pellet was resuspended in 1 mL SCEM and 
transferred to coated wells that already contained 1 mL of SCEM. Electrostatic charge was reduced by 
tapping the 6-well plate on a paper tissue soaked with Mikrozid (Mikrozid Liquid, Schülke & Mayr, 
UK). The cells were cultured for 5-7 days (Figure 8) and half of the media was changed every 2-3 
days [44]. 
 
Figure 8 Schwann cells growing on a coated well 5 days after seeding.  
A Schwann cell is indicated with the black arrow. 
 
2.2.4 Schwann cell purification procedure 
 
After 7 days in culture, SCs were purified from fibroblasts by addition of ice cold Accutasse 
for 2-3 minutes [44]. Cells were gently washed off with a pipette, collected into 15 mL tubes and 
centrifuged at 900 rpm for 5 minutes at 4 °C. The pellet was resuspended in 1 mL αMEM+ and 500 
μL of the suspension was transferred to 2 wells of an uncoated 6-well plate that already contained 2 
mL of αMEM+ media each. Electrostatic charge was reduced as mentioned previously. The plate was 
incubated for 30 minutes at 37 °C [44], allowing the fibroblasts to attach. The supernatant that mostly 
contained SCs in suspension was further centrifuged at 900 rpm for 5 min [44], cells were counted and 
100 000 cells/well were seeded in duplicates in a fresh plate coated as described previously, serving 
either as Schwann cell control (Figure 9) or for co-cultivation with the STA-NB-6 cell line.  
The SCs were seeded in media consisting of conditioned SCEM and freshly prepared SCEM 
at a ratio of 1:1 [44]. After 1.5 days, half of the media was changed to αMEM+. On day 3 after 
seeding, the entire media was changed to αMEM+ and 140 000 cells of STA-NB-6 cells were added 
for co-cultivation experiments. 
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Fibroblasts that remained in the uncoated plate after the purification procedure were kept and 
cells from one well were transferred to a coated well. They were cultivated in αMEM+ and half of the 
media was changed every 3-4 days.  
SCs and fibroblasts, as well as all cells from co-cultivation and transwell cultures, and all STA-NB-6 
cells mentioned in the following paragraphs, were cultivated for a maximum of 17 days.  
 
Figure 9 Purified Schwann cells serving as control in αMEM+, 7 days after the purification procedure. 
Fibroblasts are visible as flat, substrate adherent cells, indicated with the white arrow, between mostly di- or tri-
polar Schwann cells, indicated with the black arrow. 
 
2.2.5 Direct Schwann cell/STA-NB-6 co-cultivation  
 
STA-NB-6 cells, used for co-cultivation experiments, were not sub-cultured for at least 3-4 
days before the start of the experiment to ensure that they reach a high cell number. The media was 
changed 2 days before. Cells were maximally 80% confluent when harvested, and 140 000 cells were 
added to wells (Figure 10) already containing SCs in a drop-wise manner, thereby not disturbing cells 
growing at the bottom of the well. Cells were carefully distributed throughout the well by gentle 
shaking and electrostatic charge was reduced as described above. Half of the media was changed every 
3-4 days. Furthermore, 300 000 STA-NB-6 cells from the same flask were seeded on a coated well as 
control cells. Cells were sub-cultured at a ratio of 1:2 when necessary, and half of the media was 
changed every 3-4 days. 
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Figure 10 Schwann cells and STA NB 6 cells in αMEM+, 5 days after co-cultivation. 
The black arrow indicates Schwann cells, the white arrow indicates neuroblastoma cells. 
 
2.2.6 Transwell Schwann cell/STA-NB-6 culture  
 
SCs were seeded in duplicates, 100 000 cells/well. STA-NB-6 cells were seeded in duplicates 
on the coated surfaces of inserts (Transwell Permeable Supports, 24 mm Inserts/0.4 μm Polyester 
Membrane, Corning Inc.), in the same number as for the co-cultivation experiments (i.e. 140 000 
cells/well). The transwell (TW) inserts were then transferred on top of the wells, while ensuring there 
is enough media underneath (around 3 mL) and inside the insert (around 800 μl), so that constant 
exchange of media is allowed (Figure 11). Additionally, 300 000 STA-NB-6 cells were seeded in 
duplicates to serve as transwell controls. Half of the media was changed every 3-4 days, very carefully 
in order to avoid the STA-NB-6 cells geting transferred to the bottom well containing SCs. For this 
reason, it was important to change pipette tips between changing medium of the well and the insert, 
and to gently transfer the insert to a separate plate with the use of forceps while sub-culturing STA-
NB-6 cells.  
 
Figure 11 A scheme of a 6-well plate and a transwell insert. 
The microfluidic transwell inserts contain micropores on the bottom for ensuring constant media flow between 
the insert and the well, while prohibiting direct cell-cell contact. Figure adapted from [45]. 
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2.3 Collection of culture supernatants  
 
Culture supernatants from co-cultivation and transwell experiments, as well as from 
corresponding SCs and STA-NB-6 controls and fibroblast cultures, were collected and centrifuged at 
1200 rpm for 10 minutes at 4 °C. The supernatants were collected into labelled protein low-bind tubes 
(Protein LoBind Microcentrifuge Tubes, 1.5 mL, Eppendorf), snap-frozen and stored at -80 °C. 
 
2.4 Identification of Schwann cell-secreted factors in co-cultivation and 
transwell supernatants 
 
2.4.1 Cytokine Antibody Arrays 
  
Supernatants from 2 previous independent co-cultivation and transwell experiments with 5 
different NB cell lines (Figure 12, Sample), as well as from corresponding controls, were pooled, 
respectively, and analyzed for the presence of various cytokines, chemokines, growth factors and 
proteases (which will from now on be referred to as ´factors´ for simplicity) with cytokine antibody 
arrays (CAA or protein arrays, RayBio Human Cytokine Antibody Array G-Series 4000, RayBiotech 
Inc., USA). Each of the 5 arrays used, contained antibodies for 55 different factors printed on their 
glass surface, so, in total, 275 factors could be detected. 
It is important to note that all reagents and samples were added only to wells that contain 
printed antibodies on their glass surface (Figure 12) and that all steps that include aspiration were 
carried out with extreme care touching only the corners of the well with a pipette tip. After the protein 
arrays were equilibrated to RT, 100 μL of 1x blocking buffer was added into each well and incubated 
for 30 minutes at RT. The blocking buffer was decanted and the remaining liquid was aspirated, after 
which 100 μL/well of undiluted sample (culture supernatant) was added. The chambers were covered 
with adhesive film and incubated for 2 h at RT. The adhesive film was removed and the samples were 
aspirated. The wells were washed 3 times for 2 min with 150 μL of 1x wash buffer I. After the last 
washing step, glass slides were placed into a container, submerged in wash buffer I and washed with 
gentle rocking two times for 10 min. This step was repeated with 1x wash buffer II. After the buffer 
was decanted and aspirated, 70 μL of streptavidin fluor was added to each well, the chambers were 
covered with adhesive film and aluminum foil on top and incubated for 2 h at RT while being gently 
shaken. The streptavidin fluor was removed and the two washing steps with wash buffers I and II, 
respectively, were repeated in the same manner as described above. The glass slides were then 
removed from the frame assemblies, placed in 30 mL centrifuge tubes and washed while being gently 
shaken, two times with wash buffer I for 10 minutes, afterwards one time with wash buffer II for 3 
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minutes. The glass chips were then removed from tubes, vigorously rinsed with de-ionized water and 
dried for 20 minutes in a laminar flow hood protected from light. A simplified version of the protocol 
is shown on Figure 13. 
 
Figure 12 Scheme of samples and their distribution on protein arrays. 
The 3 subarrays, shown right, contain the same antibodies for 55 factors printed on their glass surface. 
Supernatants of the 24 samples, shown left, were added to wells of the arrays and were tested for the presence of 
these 55 factors. This procedure was performed 5 times, with 5 different arrays containing antibodies for 
different factors, so, in total, 275 different factors could be detected. The cell lines used and their characteristics 
are listed in Table 1. CTRL: control; CoCu: co-cultivation; TW: transwell; NB6: STA-NB-6; NB10: STA-NB-
10. 
 
Figure 13 Simplified scheme of the protein array protocol.  
After the addition of samples, the arrays are incubated with a cocktail of biotinylated antibodies, followed by 
fluorescently labeled-streptavidin. The signals are detected with a laser scanner. Figure adapted from RayBiotech 
CAA User Manual.  
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2.4.2 Measurement and data analysis  
 
Fluorescence signals were obtained with the GenePix 4000 array scanner (Molecular Devices) 
using the green channel (Cy3) at an excitation frequency of 532 nm and 700 PMT. The image files 
generated in this way were aligned to respective .gal files (RayBiotech) and Gene Pix Pro 7 
(Molecular Devices) was used to create .gpr files. Each spot was manually inspected on the .gpr file 
images to ensure accuracy. After background correction and normalization to the internal control, 
averages of logarithmic (log2) fluorescence intensity (FI) values of direct (CoCu) and indirect (TW) 
experiments were calculated for each cell line. The mean fluorescence intensity (MFI) ratio of these 
experiments when compared to CTRLs was calculated. The MFI values were combined for all cell 
lines and proteins that had an at least 2-fold increase in secretion in CoCu/TW experiments as 
compared to controls, together with a p ≤ 0.05 value, were selected for visualization. Data was 
uploaded into the Qlucore Omics Explorer V3.1 software to generate Principle Component Analysis 
(PCA) plots and heatmaps. 
2.5 Fluorescence activated cell-sorting of co-cultivated cells 
 
2.5.1 Fluorescence-activated cell sorting (FACS) 
 
Replicates from co-cultivation and transwell experiments, as well as their corresponding 
controls, were harvested and pooled, and the pellet was resuspended in 250 μL FACS buffer (0.1% 
FBS, 0.05% Na-azide in 1x D-PBS), or in 400 μL for samples nr. 2 and 6 (Table 2).  
Table 2 Samples used for FACS-sorting and the corresponding antibodies used. Antibody specifications are 
listed in the text. 
SAMPLE Antibody 
1 SC CTRL (αMEM+) GD2-A546 / p75NTR A647 
2 SC/STA NB 6 CoCu GD2-A546 / p75NTR A647 
3 SC TW GD2-A546 / p75NTR A647 
4 STA NB 6 TW GD2-A546 
5 STA NB 6 TW CTRL GD2-A546 
6 STA NB 6 CTRL GD2-A546 
7 Fibroblasts on coated surfaces GD2-A546 
8 Fibroblasts without coating GD2-A546 
CTRL: control; SC: Schwann cell; CoCu: co-cultivation; TW: transwell.  
Cells were transferred into FACS tubes and the following antibodies were added: 4 μL of 
p75NTR-A647 (rabbit anti human, Cell Signalling, USA; labelled with AlexaFluor647 [A20173], 
ThermoFisher Scientific, USA; diluted 1:60 in FACS buffer) and 5 μL of GD2-A546 (humanized 
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chinese hamster, POLYMUN GmbH, Austria; labelled with AlexaFluor546 [A10237], ThermoFisher 
Scientific, USA; diluted 1:10 in FACS buffer).  
The samples were incubated in the dark for 30 minutes at 4 °C, washed one time with 1 mL of 
FACS buffer and centrifuged for 5 minutes at 1200 rpm and 4 °C (all washing steps for FACS 
procedures were performed in this manner). The pellet was resuspended in 200 μL FACS buffer and 8 
μL of 2μg/mL 4', 6-Diamidino-2-Phenylindole (DAPI) solution in 1x D-PBS was added. Cells were 
filtered through a cell strainer (BD) to remove clumps and sorted at FACS Aria (BD) in tubes 
containing 1.5 mL FBS. Sorted cells were then centrifuged at 1200 rpm for 5 minutes at 4 °C, the 
pellet was resuspended in 1 mL 1x D-PBS and transferred to a RNA-free tube (RNAse free, 
Eppendorfer). After another centrifugation step, the pellet was finally resuspended in 700 μL of Qiazol 
(Qiazol Lysis Reagent, Qiagen, Germany) and stored at -80 °C. 
2.5.2 Gene expression analysis 
 
Analysis of already existing RNA sequencing (RNAseq) data was performed using a custom 
RNA-sequencing pipeline built with Anduril [46] and with Qlucore Omics Explorer V3.1 software. 
Differentially expressed genes for the dataset were selected as |logFC| > 2 and q ≤ 0.05. 
2.6 Cultivation of STA-NB-6 and STA-NB-10 NB cell lines in the presence of 
recombinant proteins identified as Schwann cell-secreted factors 
 
Table 3 Initial concentrations of the recombinant proteins analogous to Schwann cell-secreted factors selected 
for addition to STA-NB-6 and STA-NB-10 cell lines. 
 
 
 
 
 
 
 
 
 
 
 
FACTOR SOLVENT CONCENTRATION  
(ng/mL) 
PROVIDER 
IGFBP6 dH2O/0.1 % 
BSA/PBS 
100 Peprotech 
BDNF dH2O/0.1 % 
BSA/PBS 
40 Peprotech  
CNTF 5mM Na3PO4, pH 
7.5/0.1 % 
BSA/PBS 
10 Peprotech  
GDNF dH2O/0.1 % 
BSA/PBS 
30 Peprotech 
β-NGF dH2O/0.1 % 
BSA/PBS 
20 Peprotech 
PTN dH2O/0.1 % 
BSA/PBS 
50 Peprotech  
FGF7 dH2O/0.1 % 
BSA/PBS 
10 Miltenyi 
Biotec 
EGFL8 50 mM Tris HCL, 
10 mM reduced 
glutathione 
100 Abnova 
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STA-NB-10 and STA-NB-6 cell lines were seeded at a density of 250 000 cells/well and in 2 
mL of α-MEM+. Recombinant proteins were added to the media the following day, at concentrations 
(Table 3) that were chosen according to literature data. Each protein was added as a single factor, and 
a combination of all proteins was also tested with all the same concentrations as for single factors. The 
cells were sub-cultured when required, and/or 2/3 of media supplemented with recombinant factors 
was replenished every 3-4 days. All cell lines were cultivated in this manner until day 8 or day 17 after 
the start of the experiment, with the two time-points according to the procedure used for SC-NB co-
cultivation and TW experiments (manuscript in preparation). 
 
2.6.1 Cell proliferation rate measurement of STA-NB-6 and STA-NB-10 cell lines by flow 
cytometry 
 
Cells were incubated with 1 μM EdU (Life Technologies, USA) for 14 h and were harvested, 
washed 1x in αMEM+ media, then resuspended in 100 μL of FACS buffer. The cell solution was split 
and 50 μL was used for the proliferation assay, while the remaining 50 µL for the differentiation 
assay. After centrifugation at 1200 rpm for 5 min at 4 °C (all centrifugation and washing steps for the 
FACS procedure were performed in this manner), 200 μL Roti-Histofix (acid free, pH 7, phosphate-
buffered formaldehyde solution 4 %, Roth, Germany) was added and cells were fixed for 20 minutes 
at RT, protected from light. They were afterwards washed in 1 mL 1x D-PBS / 1 % FBS and the pellet 
was resuspended in 100 μL of 1x EdU Perm/Wash Click-iT EdU Alexa Fluor 647 Flow Cytometry 
Assay Kit (Thermo Fisher Scientific, USA) for permeabilization. Cells were washed with 1 mL EdU 
Perm/Wash and resuspended in 100 μL of Click-it reaction cocktail (Click-it, Life Technologies, 
USA) and incubated for 30 minutes at RT. 
After a washing step with 1 mL of the EdU Perm/Wash, cells were again resuspended in 50 
μL of the same buffer and 3 μL of the GD2-A546 antibody (humanized chinese hamster, POLYMUN 
GmbH, Austria; labelled with AlexaFluor546 [A10237], ThermoFisher Scientific, USA; diluted 1:100 
in FACS buffer) was added and incubated for 30 min at 4 °C. Samples were washed with 1 mL of the 
EdU Perm/Wash, cells were resuspended in 100 μL of the EdU Perm/Wash and 1 μL of FxCycle 
Violet stain (Thermo Fisher Scientific, USA) was added and incubated for 20 minutes at 4 °C, 
protected from light. Samples were analyzed immediately without washing with the flow cytometer 
(Fortessa, Beckton Dickinson, BD Biosciences, Austria). 
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2.6.2 Cell diferentiation measurement of STA-NB-6 and STA-NB-10 cell lines by flow 
cytometry 
 
For measurement of cell differentiation, 5 μL of the GD2-A546 antibody (specifications as 
described previously) was added to 50 μL of cell suspension and incubated for 20 minutes at 4 °C, 
protected from light. Cells were then washed with 1 mL of FACS buffer, the pellet was resuspended in 
100 μL of Cytofix/Cytoperm solution (Fixation/Permeabilization kit, BD Biosciences,Austria) and 
incubated for 20 minutes at 4 °C, protected from light. Samples were then washed with BD 
Perm/Wash buffer (diluted 1:10 with ddH2O), resuspended in 50 μL of the BD Perm/Wash and 5 μL 
of the NF200-A647 antibody (mouse anti human, Millipore, USA; labelled with AlexaFluor647 
[A20173], ThermoFisher Scientific, USA; diluted 1:40 in FACS buffer) was added and incubated for 
20 minutes at 4 °C, in the dark. Cells were finally washed one time with 1 mL of the BD Perm/Wash, 
resuspended in 100 µL Perm/Wash and analyzed with the flow cytometer (Fortessa, BD, Austria). 
 
2.7 Isolation of mouse Schwann cells from peripheral nerve tissue (Nervus 
ishiadicus) 
 
Animal studies have been approved by the Medical University of Vienna institutional review 
board for animal ethics (GZ 66.009/0274-II/3b/2010). Mice peripheral nerve tissue samples (Nervus 
ishiadicus) were provided by the Anna Spiegel Scientific Institution of the Medical University of 
Vienna. The SC isolation procedure was performed in the same manner as described for human 
peripheral nerve tissue. Since mice nerves are significantly smaller than human ones (Figure 14a), 
there was no need for cutting with a lancet, so the fascicles were pulled out directly from the fibers 
with the use of forceps, and cleaned from the remaining tissue, as much as it was possible considering 
the size. The isolated fascicles (Figure 14b) were equally distributed into 3 wells and incubated for 3h 
in 2 mL of digestion solution (αMEM+, 0.0625% collagenase Type IV (GIBCO), 0.625 U/ml Dispase 
II (SIGMA) and 3 mM CaCl) at 37 °C.  
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Figure 14 Mouse Schwann cell isolation. 
a) isolated nerves in D-PBS; b) nerve fascicles covered with αMEM. 
 
After 3 h, the tissue was mechanically resuspended with a pipette tip and the solution was 
transferred into 15 mL tubes. The wells were rinsed with αMEM+ which was added to tubes, together 
with 8 mL of fresh media. The tissue was centrifuged as stated for human SCs, and seeded on coated 
wells, in 2 mL SCEM. The cells were cultured for 3 weeks in SCEM. Due to the large amount of 
fibroblasts present, the purification procedure needed to be performed once a week and half of the 
media was changed every 3-4 days (Figure 15). 
 
Figure 15 Mouse Schwann cells growing in Schwann cell expansion media after two purification procedures.  
A lot of fibroblasts are still visible, as bigger flat cells, even after two purification rounds, due to the challenging 
isolation procedure. Fibroblasts are indicated with the white arrow, while the Schwann cells with a black one. 
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Considering the low amount of mouse SCs that could be obtained by this procedure, all of the 
mouse SCs were used for co-cultivation with the STA-NB-6 cell line. They were seeded on one coated 
well. Half of the media was changed to αMEM+ 1.5 days after seeding and 50 000 STA-NB-6 cells 
were added 3 days after seeding, with complete change of media to αMEM+. For the STA-NB-6 
control, 200 000 cells were seeded on a coated well in αMEM+. Half of the media was changed every 
3-4 days for both the co-cultivation culture and the control, and the cells were cultivated for 17 days.  
2.7.1 Cell proliferation rate measurement of the mouse Schwann cell/STA-NB-6 co-
cultivation by flow cytometry 
 
Cell proliferation of the mouse SC/STA-NB-6 co-cultivation was measured on day 17 after the 
start of the experiment, with the time-point chosen according to previous human SC co-cultivation 
experiments with NB cell lines (manuscript in preparation). The entire procedure was performed in the 
same manner as described for the STA-NB-6 and STA-NB-10 cell lines, up to the point after the 
addition of the Click-it reaction cocktail, after which samples were resuspended in 50 μL of the EdU 
Perm/Wash buffer with the addition of the following antibodies: 1μL S100-FITC (rabbit anti-mouse; 
DAKO, Austria; labelled with FITC [Z25342], ThermoFisher Scientific, USA; diluted 1:50 in FACS 
buffer); 3 μL GD2-A546 antibody (hamster anti-mouse, POLYMUN GmbH, Austria; labelled with 
AlexaFluor546 [A10237], ThermoFisher Scientific, USA; diluted 1:100 in FACS buffer); 2.5 μL 
Vimentin (rabbit anti-mouse, DAKO, Austria; diluted 1:10 in FACS buffer). 
Samples were incubated for 30 minutes at 4 °C, after which they were washed with 1 mL of 
EdU Perm/Wash and resuspended in 50 μL of the same buffer with the addition of 5 μL of Gt-anti-Ms-
A594 antibody (goat anti mouse, Li-Cor Biosciences, USA; labelled with AlexaFluor594 [A10239], 
ThermoFisher Scientific, USA; diluted 1:1000 in FACS buffer). After 20 minutes of incubation at 4 
°C, samples were washed with EdU Perm/Wash and resuspended in 100 μL of buffer. The FxCycle 
Violet stain was added in a volume of 1 μL and the samples were incubated for 20 minutes at 4 °C 
before measurement with the flow cytometer (Fortessa, BD, Austria). 
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3 RESULTS  
 
3.1 Identification of Schwann cell-secreted factors in control, co-
cultivation and transwell supernatants  
 
The identification of factors that are involved in the SC-NB crosstalk was done by a 
comprehensive analysis of the SC secretome, starting with the identification of proteins present in cell 
culture supernatants by protein arrays. 
 
3.1.1 Protein arrays identified 49 factors with an increase of secretion in co-
cultivation/transwell experiments when compared to controls 
 
For the analysis of the secretome of SCs in direct CoCu) or indirect (TW) contact with NB 
cells, when compared to the secretome of SCs and NB cells alone (controls), supernatants from 2 
independent co-cultivation and transwell experiments, respectively, with 5 different NB cell lines, as 
well as from corresponding controls, were pooled and analyzed by protein arrays. After fluorescence 
signal visualization (Figure 16b), background subtraction and data normalization, 49 factors were 
identified (Figure 17) with an at least 2-fold increased secretion in CoCu/TW experiments as 
compared to NB controls. 
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Figure 16 Protein array fluorescence signal visualization. 
a) Scheme of antibodies spotted on one of the sub-arrays. Each antibody is spotted in duplicates on the 
array to enable calculation of the average of intensities. The first three spots (upper left corner) are 
positive controls representing a dilution series of biotinylated immunoglobulins G that were used for 
data normalization. The last two spots (lower left) are negative controls, printed with a buffer already 
containing proteins, which are identical to background signals on arrays b) examples of signals obtained 
with the same sub-array in supernatants from the co-cultivation and transwell experiments of Schwann 
cells with the STA-NB-6 cell line in the upper panel, and the Schwann cells alone and STA-NB-6 cells 
alone, as controls, in the lower panel. SC: Schwann cell; NB6: STA-NB-6 cells; CoCu: co-culture; TW: 
transwell culture, CTRL: control. 
 
49 factors were increased in co-cultures/TW culture as compared to control NB cultures, while 
10 of them were differentially secreted in co-cultures when compared to SC control (Figure 17). The 
increase in secretion ranged in log2 fold changes from 1 (CFD) to 8 (CCL7), with the value of 1 
presenting a 2-fold increase (Figure 17). 
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Figure 17 49 factors identified by protein arrays. 
Cell culture supernatants of control or Schwann cell/neuroblastoma co-cultivation and transwell experiments 
were analyzed with protein arrays for the presence of 275 different cytokines and growth factors. An average 
fluorescence intensity value for the co-cultivation and transwell experiments was calculated and compared to 
values of neuroblastoma controls or Schwann cell controls. 49 proteins had an increase of secretion in CoCu/TW 
when compared to NB CTRL (shown in blue), while 10 proteins had an increase of secretion when compared to 
SC CTRL (shown in red). CoCu: co-culture; TW: transwell culture; CTRL: control; MFI: mean fluorescence 
intensity. 
 
The normalized data from the protein arrays was further uploaded into the Qlucore Omics 
Explorer to visualize the data-set and evaluate similarities and/or differences between the samples by 
generating heatmaps and PCA plots. In unsupervised hierarchical clustering, two main clusters were 
visible: direct SC-NB co-cultivation, transwell and SC control samples clustered together (Figure 18), 
while the second cluster contained all NB control samples, even though NB cell lines with various 
genetic backgrounds were used (Figure 18).  
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Figure 18 A heatmap showing unsupervised hierarchical clustering of samples based on the top 49 differentially 
secreted factors derived from the normalized protein array data. 
Up-regulated factors are shown in red, downregulated in blue. All cultures containing Schwann cells, including 
co-cultures, transwell cultures and Schwann cell controls clustered together and are abbreviated by SC, for 
simplicity. Cultures containing only NB cells are abbreviated by NB. CTRL: control, CoCu: co-culture; TW: 
transwell. 
 
Also, PCA plots (Figure 19) clearly visualized the NB-containing samples clustering distantly 
from all samples that contained SCs. 
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Figure 19 PCA plot showing clustering of all samples analyzed by CAA. 
Samples containing only neuroblastoma cells cluster away from all samples containing Schwann cells. SC/NB 
TW: Schwann cell/neuroblastoma transwell culture; SC/NB CoCu: Schwann cell/neuroblastoma co-culture; SC: 
Schwann cell control; NB: neuroblastoma control; NB TW: neuroblastoma transwell controls; aMEM CTRL: 
aMEM media control.  
 
3.2 Prioritization of candidate neurotrophic/neuritogenic factors 
 
Literature research was performed for each of the 49 identified factors to investigate whether 
they suit the criteria for further functional validation on NB cell lines. As sources for literature 
research UniProtKB (www.uniprot.org/), the NCBI gene database (www.ncbi.nlm.nih.gov/gene) and 
PubMed (www.ncbi.nlm.nih.gov/pubmed; with search terms: [factor name] and [Schwann cells]; 
[factor name] and [neuroblastoma]) were used. 
Twelve, out of 49 proteins, were shown to have functions in immune cell attraction (Figure 
20; Table 4), most of them being cytokines and chemokines, such as CCL7, CXCL8, CXCL3, 
CXCL2, CCL11, CCL20, CXCL6, CCL13, CCL2, CCL8, PF4, or to be involved in the activation of 
complement, such as CFD.  
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Figure 20 Functional annotation of 49 differentially secreted factors based on literature research.  
The bars and corresponding values are the same as in Figure 17, only annotated. Factors that were shown to be 
involved in immune cell recruitment, to have tumor-promoting functions, or to function as proteases, receptors 
or components of the extracellular matrix were excluded from further analysis. To obtain a complete picture, 13 
candidate factors were looked up in gene expression data. MFI: mean fluorescence intensity. 
  
Table 4 Twelve factors involved in phagocyte recruitment.  
Protein names and proposed functions are according to www.uniprot.org. 
 
FACTOR 
 (gene symbol) 
PROTEIN NAME 
 
PROPOSED FUNCTION 
CCL7 C-C motif 
chemokine 7 
Chemotactic factor that attracts monocytes and 
eosinophils, but not neutrophils. 
CXCL8 Interleukin-8 Attracts neutrophils, basophils, and T-cells, but not 
monocytes. 
CXCL3 C-X-C motif 
chemokine 3 
Chemotactic activity for neutrophils. 
CXCL2 C-X-C motif 
chemokine 2 
Hematoregulatory chemokine. Expressed at sites of 
inflammation.  
CCL11 Eotaxin Promotes the accumulation of eosinophils. 
CCL20 C-C motif 
chemokine 20 
Attracts lymphocytes and, slightly, neutrophils, but not 
monocytes. 
CXCL6 C-X-C motif 
chemokine 6 
Chemotactic for neutrophil granulocytes. 
CCL13 C-C motif 
chemokine 13 
Attracts monocytes, lymphocytes, basophils and 
eosinophils, but not neutrophils. 
CCL2 C-C motif 
chemokine 2 
Attracts monocytes and basophils, but not neutrophils or 
eosinophils. 
CCL8 C-C motif 
chemokine 8 
Attracts monocytes, lymphocytes, basophils and 
eosinophils. 
PF4 Platelet factor 4 Chemotactic for neutrophils and monocytes. Released 
during platelet aggregation. 
CFD Complement 
factor D 
Complement activation. 
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Thirteen, out of 49 factors, were shown to have tumor-promoting functions (Figure 20; Table 
5), such as IL11, SERPINE1, VEGFA, PROK1, MIF, IGFBP1, IGFBP2, PGF, ANGPT1, VEGFC and 
HGF, and/or to be involved in angiogenesis, e.g. ANG, VEGFA, SPP1, ANGPT1, VEGFC, MIF.  
Table 5 Factors with a tumor-promoting and/or pro-angiogenic effect.  
Protein names and proposed functions are according to www.uniprot.org., if not otherwise stated. 
 
FACTOR 
 (gene symbol) 
PROTEIN NAME 
 
PROPOSED FUNCTION 
ANG Angiogenin Angiogenic factor that supports primary and 
metastatic tumor growth [47]. 
IL11 Interleukin-11 Stimulates the proliferation of hematopoietic stem 
cells and megakaryocyte progenitor cells. 
SERPINE1 Plasminogen activator 
inhibitor 1 
Serine protease inhibitor. Shown to promote 
metastasis in neuroblastoma [48]. 
SPP1 Osteopontin Produced by various tumor cells and is suggested 
to be involved in angiogenesis [49]. 
VEGFA Vascular endothelial 
growth factor A 
Induces endothelial cell proliferation, promotes 
cell migration, inhibits apoptosis and induces 
permeabilization of blood vessels. 
PROK1 Prokineticin-1 Directly influences neuroblastoma progression by 
promoting the proliferation and migration of 
neuroblastoma cells. 
MIF Macrophage migration 
inhibitory factor 
It has been linked to fundamental processes such 
as control of cell proliferation, cell survival, 
angiogenesis, and tumor progression [50]. 
IGFBP1 Insulin-like growth factor-
binding protein 1 
Promotes cell migration. 
IGFBP2 Insulin-like growth factor-
binding protein 2 
Binds to the ECM and enhances proliferation and 
metastatic behavior of neuroblastoma cells [51]. 
ANGPT1 Angiopoietin-1 Plays an important role in the regulation of 
angiogenesis, endothelial cell survival, 
proliferation, migration, adhesion and cell 
spreading. 
PGF Placenta growth factor Promotes tumor cell growth. 
VEGFC Vascular endothelial 
growth factor C 
Growth factor active in angiogenesis, and 
endothelial cell growth, stimulating their 
proliferation and migration. 
HGF Hepatocyte growth factor 
receptor 
Increase in HGF/c-Met expression was correlated 
with enhanced invasiveness and activation of 
proteases degrading the extracellular matrix [52]. 
 
Considering their phagocyte attracting and tumor-promoting functions, these proteins were 
excluded from further validation assays in NB cell lines. In addition, 11 factors were excluded because 
of other functions (Figure 20; Table 6), such as MMP10, MMP3 and PI3 which are proteases; 
TNFRSF1A, EGFR, PLAUR, AXL, IL6ST and TNFRSF11B that are receptors; or components of the 
extracellular matrix, e.g. NID1 and DCN. 
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Table 6 Factors excluded as candidates based on their functions as proteases, receptors or components of the 
extracellular matrix.  
Protein names and proposed functions are according to www.uniprot.org.  
 
FACTOR 
 (gene symbol) 
PROTEIN NAME 
 
PROPOSED FUNCTION 
MMP10 Stromelysin-2 Can degrade fibronectin, gelatins of type I, III, IV, 
and V; weakly collagens III, IV, and V. 
MMP3 Stromelysin-1 Can degrade fibronectin, laminin, gelatins of type I, 
III, IV, and V; collagens III, IV, X, and IX, and cartilage 
proteoglycans. 
PI3 Elafin Neutrophil and pancreatic elastase-specific 
inhibitor of skin. 
TNFRSF1A Tumor necrosis factor 
receptor superfamily 
member 1A 
Receptor for TNFSF2/TNF-alpha and homotrimeric 
TNFSF1/lymphotoxin-alpha. 
EGFR Epidermal growth factor 
receptor 
Receptor tyrosine kinase binding ligands of the EGF 
family. 
PLAUR Urokinase plasminogen 
activator surface 
receptor 
Acts as a receptor for urokinase plasminogen 
activator. 
AXL Tyrosine-protein kinase 
receptor UFO 
Receptor tyrosine kinase that transduces signals 
from the extracellular matrix into the cytoplasm by 
binding growth factor GAS6. 
NID1 Nidogen-1 Sulfated glycoprotein widely distributed in 
basement membranes and tightly associated with 
laminin. 
IL6ST Interleukin-6 receptor 
subunit beta 
Signal-transducing molecule. The receptor systems 
for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 utilize 
it for initiating signal transmission. 
TNFRSF11B Tumor necrosis factor 
receptor superfamily 
member 11B 
Acts as decoy receptor for TNFSF11/RANKL and 
thereby neutralizes its function in 
osteoclastogenesis. 
DCN Decorin May affect the rate of fibrils formation. 
 
The remaining 13 factors (Figure 20; Table 7) were further analyzed to confirm their 
upregulation on RNA level and investigate whether they are upregulated by SCs or NB cells in co-
cultures and transwell cultures, as well as to confirm the expression of the corresponding receptors on 
NB cell lines. The protein array data were therefore compared to gene expression data (RNA-seq) of 
FACS-sorted SCs and NB cells from co-cultures, transwell cultures and controls, and analyzed by 
Qlucore Omics Explorer. 
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Table 7 13 candidate factors that were further analyzed by gene expression analysis.  
Protein names and proposed functions are according to www.uniprot.org., if not otherwise stated. 
 
FACTOR 
 (gene symbol) 
PROTEIN NAME 
 
PROPOSED FUNCTION 
IL6 Interleukin-6 It induces myeloma and plasmacytoma growth 
and induces nerve cells differentiation. Silverman 
et al. [53] showed that neuroblastoma cells induce 
production of IL6 in stromal cells. 
CXCL5 C-X-C motif chemokine 5 Shown to have an effect on nerve regeneration by 
inducing neurite growth [54]. 
FSTL3 Follistatin-related protein 
3 
Antagonizing protein for members of the TGF-beta 
family that is involved in differentiation of 
hematopoietic cells. 
GDF15 Growth/differentiation 
factor 15 
Shown to be secreted by Schwann cells in the 
lesioned peripheral nervous system [55]. 
TGFBI Transforming growth 
factor-beta-induced 
protein ig-h3 
Shown to significantly reduce proliferation and 
invasion of neuroblastomas in vitro and in vivo 
[56]. 
CCL5 C-C motif chemokine 5 Together with GPR75, may play a role in neuron 
survival. 
IGFBP6 Insulin-like growth factor-
binding protein 6 
A member of the IGF system shown to be 
associated with the growth-arrest in 
neuroblastoma cells [57]. 
IGFBP3 Insulin-like growth factor-
binding protein 3 
Exhibits IGF-independent anti-proliferative and 
apoptotic effects mediated by its receptor 
TMEM219/IGFBP-3R. 
FGF7 Fibroblast growth factor 7 Plays an important role in the regulation of 
embryonic development, cell proliferation and cell 
differentiation. 
PDGFA Platelet-derived growth 
factor subunit A 
It´s expression was shown to be significantly 
associated with patient survival in advanced-stage 
tumors [58]. PDGF isoforms were also shown to 
induce morphological changes showing neuronal 
cell maturation in a wide variety of neural crest-
derived human tumor cell lines [59]. 
CXCL16 C-X-C motif chemokine 16 It´s receptors were shown to be involved in the 
retention of metastatic neuroblasts in the bone 
marrow through interaction with CXCL16-
expressing stromal cells [60]. 
TIMP1 Metalloproteinase 
inhibitor 1 
Functions as a growth factor that regulates cell 
differentiation, migration and cell death, and 
activates cellular signaling cascades via CD63 and 
ITGB1. 
FST Follistatin Involved in differentiation of hematopoietic cells. 
 
Additionally, 6 neurotrophins (Table 8) known from previous research for their effects in the 
CNS or PNS were also considered as candidates. Since these proteins were not included on the protein 
arrays (PTN and EGFL8), or not shown as differentially secreted (BDNF, GDNF, CNTF and NGF), 
their gene expression levels were also analyzed and visualized by Qlucore. 
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Table 8 Factors chosen from literature research.  
Six neurotrophins were chosen in addition to the ones identified by protein arrays. All the proposed roles are 
according to www.uniprot.org., unless otherwise stated. 
FACTOR 
 (gene symbol) 
PROTEIN NAME 
 
PROPOSED FUNCTION 
BDNF Brain-derived 
neurotrophic factor 
During development, promotes the survival and 
differentiation of selected neuronal populations of 
the peripheral and central nervous systems. 
Participates in axonal growth, path finding and in the 
modulation of dendritic growth and morphology. 
GDNF Glial cell line-derived 
neurotrophic factor 
Neurotrophic factor that enhances survival and 
morphological differentiation of dopaminergic 
neurons and increases their high-affinity dopamine 
uptake. 
CNTF Ciliary neurotrophic 
factor 
CNTF is a survival factor for various neuronal cell 
types. Seems to prevent the degeneration of motor 
axons after axotomy. 
NGF Beta-nerve growth 
factor 
Activates cellular signaling cascades through receptor 
tyrosine kinases to regulate neuronal proliferation, 
differentiation and survival. 
PTN Pleiotrophin Secreted growth factor that induces neurite 
outgrowth. Binds the receptor ALK, which induces 
activation of the mitogen-activated protein kinase 
pathway, an important step in the anti-apoptotic 
signaling of PTN and regulation of cell proliferation. 
EGFL8 Epidermal growth 
factor-like protein 8 
Chosen based on previous research performed by 
Weiss, Taschner-Mandl et al. [44]. 
 
3.3 Gene expression analysis of FACS-sorted cells from co-cultivation, 
transwell and control cultures 
 
3.3.1 Gene expression analysis led to selection of 8 factors 
 
Gene expression (RNA-seq) data used in this master thesis was previously obtained by RNA-
sequencing of FACS-sorted SCs and STA-NB-6 cells from the same co-culture, transwell culture and 
controls from which supernatants were used for protein arrays, together with additional SC samples 
and NB cell lines (STA-NB-2, STA-NB-7 and STA-NB-15 cells).  
This RNA-seq dataset was used to analyze mRNA levels of the 13 factors selected with 
protein arrays and 6 additional neurotrophins selected from literature in different NB cell lines, SCs 
alone and one co-cultivation/transwell experiment. In addition, the expression of their corresponding 
receptors on different NB cell lines was investigated, since the factors can act on NB cells only if their 
corresponding receptors are present on these cells. 
Based on the gene expression data, 2 factors, out of the 13 selected with protein arrays and 
literature research, were chosen as candidates, IGFBP6 and FGF7. IGFBP6 was highly expressed by 
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SCs, but not by NB cells (Figure 21) and the recently described receptor PHB2, an IGF signaling-
independent receptor [61], was highly expressed in NB, while SCs had very low levels (Figure 21). 
Similarly, FGF7 was high in SCs (Figure 21) and its receptor FGFR2 [62] present at high levels on 
NB cells (Figure 21).  
All the 6 additional neurotrophic factors, chosen from literature, were, as expected, highly 
expressed by SCs, with the exception of CNTF and PTN, being highly expressed by both SCs and NB 
cells (Figure 21). CNTFR, the receptor for CNTF, was upregulated by NB cells (Figure 21), although 
LIFR and IL6ST, parts of the same receptor complex [63], were upregulated by both SCs and NB cells 
(Figure 21). PTN binds several receptors, some of which are PTPRZ1 [64-67] and PTPRA [68], that 
were mainly upregulated by SCs (Figure 21), but also ALK [69, 70] that was expressed at high levels 
in NB cells (Figure 21).  
NGFR and GFRA1, receptors of NGF and GDNF [71], respectively, were highly expressed in 
SCs (Figure 21), but comparison to unrelated cell types (mononuclear cells) showed that both 
receptors are also highly expressed by NB cells, although at lower levels as compared to SCs (data not 
shown). Moreover, the other receptors for NGF and GDNF, NTRK1 and RET [71], respectively, were 
upregulated only in NB cells (Figure 21). NGFR, like NTRK2 [71], also binds BDNF [71], which was 
mostly upregulated in NB cells (Figure 21). It is currently unknown to which receptor EGFL8 binds, 
since its structure was just recently described and it has so far unknown function [72].  
Taken together the 8 selected factors showed high mRNA levels in SC samples and high 
expression of the corresponding receptors in NB cells making them suitable candidates for functional 
validation in NB cell cultures. 
 
34 
 
 
Figure 21 Heatmaps showing RNA expression levels of the 8 selected Schwann cell-secreted proteins and their 
corresponding receptors in different neuroblastoma and Schwann cell samples. 
a) Expression levels of the selected factors, b) expression levels of the corresponding receptors. The 
receptors correspond to their ligands as follows: BDNF – NGFR, NTRK2, ; GDNF – GFRA1, RET; 
CNTF – LIFR, CNTFR, IL6ST; NGF – NGFR, NTRK1; PTN –ALK, PTPRZ1, PTPRA; IGFBP6 –  
PHB2; FGF7 – FGFR2. The receptor for EGFL8 is unknown. Samples were abbreviated according to 
cell type for simplicity. SC: Schwann cell; NB: neuroblastoma. 
 
3.4 Functional validation of 8 candidate factors  
  
In order to functionally validate the 8 candidate factors, their corresponding recombinant 
proteins were added at different concentrations, separately and in combination, to cell media of two 
NB cell lines derived from aggressive tumors, STA-NB-6 and STA-NB-10. The STA-NB-6 cell line 
was previously demonstrated to be sensitive to direct/indirect interaction with SCs in co-cultures, and 
STA-NB-10 to be less sensitive (manuscript in preparation). Flow cytometry-based assays were used 
to measure the reduction of cell proliferation and induction of cell differentiation of NB cells, as well 
as to define the concentration and combination needed to induce these effects. 
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3.4.1 Flow cytometry-based cell proliferation and differentiation rate measurement 
confirmed the proposed effects of selected proteins on STA-NB-6 cells 
 
In these experiments, NF200 expression, as marker for neuronal differentiation, and EdU 
incorporation, as indicator of proliferative activity, were measured by flow cytometry-based assays.  
First, STA-NB-10 cells were cultivated in the presence of candidate neurotrophic/neuritogenic 
factors for 17 days. In previous co-culture experiments with SCs, the STA-NB-10 cell line showed 
only moderate responsiveness regarding inhibition of proliferation, and did not show any 
responsiveness concerning differentiation (manuscript in preparation). Similarly, there was no 
significant effect of any of the factors at the tested concentrations with regard to cell proliferation or 
differentiation on the STA-NB-10 cell line. Some of the factors, e.g. IGFBP6, BDNF, CNTF, GDNF 
and PTN, even slightly increased proliferation (Figure 22), although not significantly, while EGFL8 
slightly decreased cell proliferation on day 17. Combination of all 8 factors also had no significant 
effect, although a slight decrease of cell proliferation is visible on day 17 (Figure 22). 
 
Figure 22 Relative proliferation and differentiation rates of the STA-NB-10 cell line cultivated in the presence or 
absence (control) of chosen recombinant proteins for 17 days.   
Mean+/-SEM values of normalized EdU incorporation data and normalized NF200 MFI values from 3 
independent experiments were calculated to analyze the relative effect on cell proliferation and neuronal-like 
differentiation, respectively. The single factors showed no significant effect on cell differentiation at these 
concentrations, while IGFBP6, GDNF, CNTF, BDNF and PTN even slightly increased cell proliferation. The 
combination of all factors slightly decreased cell proliferation on day 17, but had no effect on cell diferentiation. 
EGFL8 data was derived from one experiment and was thus not considered for statistical analysis, although a 
slight decrease of cell proliferation is visible on day 17. CTRL: control; MFI: mean fluorescence intensity. 
 
Second, STA-NB-6 cells were cultured in the presence of 8 candidate factors, separately or in 
combination, for 8 and 17 days, respectively. This cell line showed strong responsiveness to SCs in 
co-cultures already on day 8 in previous experiments, which was even more pronounced on day 17 
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(manuscript in preparation). However, addition of factors demonstrated no significant changes of 
proliferation (Figure 23a), nor differentiation (Figure 23b) on day 8. Significantly decreased 
proliferation in the presence of NGF (20 ng/mL) and PTN (50 ng/mL) (Figure 23a) was shown on day 
17, and increased neuronal-like differentiation in the presence of PTN on day 17 (Figure 23b). NGF 
also had a pronounced effect on cell differentiation, although it was not statistically significant (Figure 
23b).  
 For PTN, two cell populations were clearly visible by flow-cytometry analysis of 
differentiation (Figure 24a, differentiation, PTN), one expressing low levels of NF200 and the second 
high levels, probably representing more differentiated (mature) NB cells. Neuronal-like differentiation 
induced by PTN and NGF, as compared to CTRL, was also confirmed by axonal outgrowth, as 
visualized by phase contrast microscopy (Figure 24b, NGF; PTN; CTRL).  
All other factors, except FGF7 and BDNF, showed a trend towards increased differentiation 
(Figure 23b) and decreased proliferation (Figure 23a) on day 17 at the initial tested concentrations, 10 
and 40 ng/mL, respectively. For FGF7 and BDNF, that did not show any effect on cell proliferation or 
differentiation at initial concentrations, concentration was doubled in additional experiments, and 
BDNF showed a more pronounced effect at 80 ng/mL on both cell proliferation (Figure 23a) and 
differentiation (Figure 23b), when compared to the lower concentration used. FGF7, however, failed 
to reduce cell proliferation or induce differentiation even at higher concentration, 20 ng/mL (Figure 
23a, b).  
Even though only one experiment was performed with EGFL8 (100 ng/mL), it showed an 
unexpected effect on day 8, with an increase of cell proliferation (Figure 23a) and decrease of cell 
differentiation (Figure 23b), while on day 17, a pronounced effect in decreasing cell proliferation 
(Figure 23a) and increasing cell differentiation (Figure 23b).  
Surprisingly, combination of all factors at tested concentrations had no significant effect on 
cell proliferation at both time-points (Figure 23a), while cell differentiation was affected on day 17, 
although not significantly (Figure 23b). 
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Figure 23 Relative cell proliferation and differentiation rate of the STA-NB-6 cell line, 8 or 17 days, 
respectively, after the addition of recombinant proteins. 
a) Mean+/-SEM values of normalized EdU incorporation data from 3 independent experiments were 
calculated to analyze the relative effect on cell proliferation. Most of the factors, except NGF and 
EGFL8, showed no effect on day 8. NGF and PTN significantly decreased cell proliferation on day 17 
at tested concentrations. All factors, except FGF7 and BDNF, showed a tendency towards decreased 
proliferation at initial tested concentrations, while for FGF7 and BDNF the initial concentration was 
doubled. FGF7 failed to decrease cell proliferation even at the double concentration, while BDNF 
showed a pronounced effect both on day 8 and day 17. Combination of all factors had no effect on day 
8, nor day 17. EGFL8, although only tested in one experiment and thus not considered for statistical 
analysis, showed an unexpected effect on day 8 with an increase of cell proliferation, and a pronounced 
decrease on day 17. 
b) Mean+/-SEM values of normalized NF200 MFI values from 3 independent experiments were calculated 
to analyze the relative effect on cell differentiation. None of the factors showed a significant effect on 
day 8, while PTN showed a significant effect in increasing cell differentiation on day 17 at the tested 
concentration. NGF also had a pronounced effect on cell differentiation, although it was not significant. 
All factors, except FGF7, showed a tendency towards increasing cell differentiation at tested 
concentrations on day 17. EGFL8 showed an unexpected effect, with a decrease of cell differentiation 
on day 8 and a pronounced increase on day 17. Asterisks indicate statistically significant differences 
compared to CTRL, *p ≤ 0.05. CTRL: control; MFI: mean fluorescence intensity. 
 
38 
 
 
Figure 24 Representative flow cytometry plots and microscopic images.  
a) Representative plot of the flow-cytometry gating strategy. Neuroblastoma cells are detected as GD2-A546 
positive cells. b) The proliferation rate of neuroblastoma cells is measured as the percentage of EdU 
incorporation, while c) the differentiation rate as the expression value of the NF200 marker. NF200-APC 
histograms show MFI values for STA-NB-6 cells cultured in the presence NGF or PTN for 17 days, respectively, 
as compared to untreated control. On the histogram for PTN (right), two cell populations are clearly visible - one 
expressing low levels of NF200, presented by the lower peak, and the second high levels, presented with the 
higher peak, probably representing more differentiated neuroblastoma cells. This is also visible on the histogram 
for NGF (middle), although less, whereas not visible at all for control cells (left). d) Representative phase 
contrast microscopy images of cultures. The prolongation of neural processes upon cultivation in the presence of 
PTN and NGF is clearly visible when compared to control. The microscopic images in d) and NF200-APC 
histograms in c) are not from the same experiments. NB: neuroblastoma cells; CTRL: control; MFI: mean 
fluorescence intensity value. 
 
 
3.5 Pilot study: Isolation of Schwann cells from mouse peripheral nerve 
tissue and co-cultivation with the STA-NB-6 cell line 
 
A pilot experiment was conducted to assess whether it is possible to culture SCs isolated from 
mouse peripheral nerves, and whether their in vitro co-cultivation with human NB cells will have an 
effect on NB cell proliferation and differentiation. The human SC isolation procedure was successfully 
adapted to mouse peripheral nerve tissue and the mouse SC could be cultivated and further co-
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cultivated with the STA-NB-6 cell line (Figure 25a) in the same manner as with human SCs, although 
the number of mouse SCs obtained was rather low. Furthermore, it was possible to measure the rate of 
STA-NB-6 cell proliferation in co-cultures with mouse SCs (Figure 25b), proving that the isolation 
and cultivation of SCs from mouse peripheral nerve tissue and co-cultivation with human NB cells is 
feasible. However, no effect on NB proliferation was observed, probably due to the very low numbers 
of mouse SCs used in this experiment.  
 
Figure 25 Co-cultivation of mouse Schwann cells with the STA-NB-6 cell line and flow cytometry measurement 
of the cell proliferation rate of STA-NB-6 cells. 
a) Microscopic image of the mouse Schwann cell/STA-NB-6 co-cultivation. The white arrow indicates Schwann 
cells, and the black one neuroblastoma cells. Due to the low number of Schwann cells obtained by isolation from 
mouse peripheral nerve tissue, the number of neuroblastoma cells added was also lower. The gating strategy of 
the flow cytometry cell proliferation rate measurement can be seen on flow cytometry plots, with all cells shown 
on b) the FSC/SSC plot; c) separate gating into GD2+S100- neuroblastoma cells, GD2-S100+ Schwann cells and 
GD2-S100- fibroblasts on the GD2/S100 plot; d) an univariate (single-parameter) histogram showing 
incorporation of EdU for measurement of cell proliferation with a peak for GD2+S100- NB cells negative for 
EdU incorporation, on the left side, and EdU positive cells, on the right. NB: neuroblastoma cell; FB: fibroblasts; 
SC: Schwann cells. 
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4 DISCUSSION  
 
SCs are suggested to be essential for the benign clinical behavior of ganglioneuroma, acting 
via neuritogenic, anti-proliferative and pro-apoptotic signals. The exact mechanism of this unique 
tumor-stroma crosstalk is, however, still unknown. In this study, SC-secreted factors and 
corresponding receptor expression was investigated using protein arrays and RNA-sequencing data. 
This study identified PTN as a potential factor involved in the SC-NB interaction. The in vitro 
experiments conducted here showed that addition of 50 ng/mL of recombinant PTN to cell media for 
17 days causes a reduction of cell proliferation and induction of neuronal-like differentiation of a NB 
cell line derived from an aggressive tumor, STA-NB-6. The growth-impairing effect of PTN was 
demonstrated in vitro by cultivation of STA-NB-6 cells in the presence of the recombinant protein and 
measured by flow cytometry-based readout assays. In addition to PTN, NGF was also shown to have a 
significant proliferation-reducing effect on STA-NB-6 cells, which confirms previous investigations of 
NGF in NTRK1/TrkA over-expressing neuroblastoma cells [58, 73]. 
4.1 PTN-a mediator of the SC-NB interaction  
 
In this study, PTN was recognized as a potential factor involved in the SC-NB interaction. 
Recombinant PTN was shown to decrease proliferation and induce neuronal-like differentiation of 
STA-NB-6 cells in vitro. This sheds new light on its role in disease and tumorigenesis, since it is 
considered to be a tumor growth- and angiogenesis-inducing factor [74, 75], and makes PTN suitable 
for further testing in other NB cell lines, as well as other tumor types. 
PTN is a secreted neurite outgrowth-promoting factor usually associated with the extracellular 
matrix that acts in several tissues through different receptors. In the CNS, it is widely expressed during 
development [76] and it regulates neurogenesis [77], neural migration [78] and differentiation [79, 80]. 
The expression in the adult brain is constricted to certain regions, such as the hippocampus [81], where 
PTN is involved in learning and long-term memory processes [82]. In the PNS on the other hand, its 
function has so far mostly been investigated in the context of nerve regeneration after peripheral nerve 
injury [15, 83]. The possibility that PTN is secreted by tumor-associated SCs in ganglioneuroma and 
may thus be linked to the benign phenotype of these tumors was, until now, not thoroughly 
interrogated.  
It is well known that PTN is associated with the pathogenesis of neurodegenerative diseases, as 
well as with inflammation and cancer development. Unlike some tumors, such as breast carcinoma, in 
which PTN is highly expressed and implicated as a tumor-growth factor [84, 85], in neuroblastoma, 
low levels of PTN are correlated to poor prognosis [86]. Interestingly, PTN expression was shown to 
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be significantly higher in favorable types of neuroblastoma than in unfavorable ones [86-88]. In line 
with the findings demonstrated in this study, Nakagawara et al. hypothesized in their work that it is 
possible that PTN ‘acts on neuroblastoma cells to potentiate the neuronal and/or Schwannian 
differentiation’ [86]. Since ganglioneuromas are composed of few fully differentiated ganglionic cells 
that are surrounded by a dense SC stroma, it is very likely that the highly expressed PTN in 
ganglioneuromas originates from SCs. Transcriptome analysis of the SC fraction of ganglioneuromas 
could clarify this open question. In the gene expression data presented in this work, PTN was 
expressed by SCs, but also by NB cells. It was previously observed that highly aggressive NB cells, 
especially those with MYCN amplification, express much lower amounts of PTN than cells without 
MYCN amplification [86, 87]. Similarly, this study showed slightly higher expression of PTN by the 
MYCN non-amplified STA-NB-6 cell line, while STA-NB-7 and STA-NB-15, both MYCN-amplified 
cell lines, presented very low PTN expression. 
The preliminary in vitro co-cultivation data suggesting the tumor growth-inhibiting and 
differentiation-inducing effect of SCs on NB cells (manuscript in preparation), together with the 
validation of the anti-tumor effect of PTN on STA-NB-6 cells presented in this work, indicate that 
PTN might indeed be one of the factors involved in the SC-NB interaction that provoke neuroblastoma 
maturation. 
4.2 PTN signaling in neuritogenesis and neuroblastoma 
 
PTN’s neurite-outgrowth abilities were demonstrated to be conducted through the ALK (anti-
anaplastic lymphoma kinase) receptor [89]. Although ALK was shown to be more active in favorable 
neuroblastoma tumor types than in unfavorable ones [87], its activation is considered to frequently 
initially occur in neuroblastoma oncogenesis [87]. In 8-10% of neuroblastoma patients, ALK 
activation is due to activating point mutations in its tyrosine kinase domain [90, 91]. It is speculated, 
however, that ALK activation in many tumor types, as well as neuroblastoma, depends on the activity 
of a ligand [87, 90, 92].  
ALK has two known ligands belonging to the same family of growth factors, PTN and MK 
(midkine) [93]. MK was shown to compete with PTN for ALK binding [70]. Opposite to PTN, high 
MK levels in NB are correlated with poor prognosis [68, 86], and MK was shown to be expressed 
relatively weakly in ganglioneuroma [86]. Moreover, MK occurs frequently and at high levels in all 
stages of neuroblastoma [86, 93], especially in undifferentiated and aggressive neuroblastomas, and 
MYCN amplified tumor cells [86]. ALK activation and overexpression were shown to be concomitant 
with MK upregulation in neuroblastoma [87]. The growth-impairing effects of PTN on STA-NB-6 
cells demonstrated in this work, suggests that the two ligands, although sharing structural similarities 
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[93], might have opposite effects on ALK activation in neuroblastoma, which may depend on the 
equilibrium of both factors in the tumor microenvironment. 
In the MYCN amplified NB cell lines used in this study, i.e. STA-NB-7 and STA-NB-15, ALK 
expression was elevated as compared to the MYCN non-amplified STA-NB-6 cell line, in which it was 
low, even though PTN had a significant effect on this cell line. Phosphorylation of ALK in cells 
should be evaluated in future studies to investigate ALK activation, since it was shown that the ligand-
induced ALK activation might be mediated through alternative mechanisms [94], suggesting that PTN 
signaling might be conducted through various receptors. Another receptor that binds PTN is PTPRZ1 
(protein tyrosine phosphatase receptor type Z1) [64, 65], which was shown to be predominantly 
expressed in the CNS [95]. PTN acts as an inhibitory ligand for PTPRZ1 by inducing oligomerization 
of the receptor, thereby preventing its tyrosine phosphatase activity [96]. During reparative re-
myelination in the CNS, PTN acts through PTPRZ1 to promote oligodendrocyte differentiation [67]. 
In this study, PTPRZ1 was shown to be highly upregulated by SCs, in which it was shown to act as the 
putative F3 receptor [97]. This receptor has, so far, not been investigated in NB, which might be 
interesting to pursue in future studies, since it was showed that PTN stimulates tyrosine 
phosphorylation of ALK through the PTN/PTPRZ1 signaling pathway [98]. An alternative receptor 
that can interact with PTN is PTPRA (protein tyrosine phosphatase receptor type A, or LRP) [68, 99]. 
This receptor was shown to be upregulated and involved in the DMSO-induced neuronal 
differentiation of N1E-115 neuroblastoma cells [100]. High PTPRA expression in SCs was 
demonstrated in this study, but also in STA-NB-7 and STA-NB-15, MYCN amplified cell lines, 
suggesting that PTN might act through PTPRA in MYCN amplified cell lines. 
Other reported receptors that could be analyzed in further experiments are neuropilin-1 [75], 
N-syndecan [101], integrin α4β1, α6β1 [102]. Altogether, PTN signaling is most likely conducted 
through multiple receptors, and PTN and corresponding receptor expression analysis should be 
expanded to other cell lines to investigate the mechanism involved. 
4.3 Confirmation of the growth-impeding effects of NGF 
 
The results of this study demonstrated that the patient-derived NB cell line, STA-NB-6, 
expresses TrkA and responds to NGF stimulation by decreased proliferation, neuronal differentiation 
and neurite outgrowth. This is also in concordance to previous knowledge, since TrkA activation, 
besides inducing differentiation, can inhibit angiogenesis, mediate apoptosis and cause growth arrest 
[58]. Interestingly, NTRK1 (TrkA), high-affinity receptor for NGF, has similar expression patterns as 
PTN in NB. Ganglioneuromas and favorable NBs were shown to express high levels of TrkA [36, 
103]. TrkA expression is also very low or absent in MYCN-amplified cell lines [37, 73]. In this study 
the MYCN non-amplified cell line, STA-NB-6, had higher TrkA expression levels than the MYCN-
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amplified STA-NB-15, explaining at least in part the ability of the STA-NB-6 cell line to respond to 
SCs. 
4.4 Examination of the SC secretome  
 
The comprehensive analysis of extracellular factors produced by human SCs performed in this 
study revealed 49 differentially secreted proteins in co-cultures/TW cultures compared to NB CTRL, 
and 10 proteins compared to SC CTRL, suggesting that the majority of factors are secreted by SCs. 
Moreover, the heatmap and PCA plot presenting protein array data demonstrated that all cultures 
containing Schwann cells, including co-cultures, transwell cultures and Schwann cell controls, cluster 
together and distantly from NB-containing samples, thereby, again suggesting a dominant contribution 
of Schwann cells to the analyzed secretome. These results, thus, together with the various roles that 
SCs exert in physiological and pathological conditions [4, 12, 13, 16] known from literature, justify 
the lower number of proteins presented in co-cultures/TW cultures when compared to SC CTRL. 
Most of the 49 identified proteins had functions already attributed to SCs, but some of them 
have not been implicated in SC function yet. Among those, 2 potentially neuritogenic factors, IGFBP6 
and FGF7, were tested in in vitro assays. FGF7 failed to reduce cell proliferation or induce 
differentiation at both concentrations tested, 10 and 20 ng/mL, respectively. IGFBP6, however, 
showed a slight decrease of proliferation and increase of differentiation at a concentration of 100 
ng/mL. IGFBP6 was in previous research mostly examined in the context of its IGF-II binding 
abilities and was demonstrated to inhibit NB cell growth in vitro and in vivo [57, 104]. However, an 
IGF-independent role of IGFBP6 was recently discovered [61], involving signaling through PHB-2. 
PHB2 was upregulated in all NB cell lines analyzed in this work, suggesting that in addition to PTN 
and NGF, IGFBP6 is a potential SC-secreted protein that can affect NB growth and differentiation. 
Evaluation of 6 additional proteins known from literature, revealed EGFL8 as a potential 
proliferation-reducing and neuritogenesis-inducing factor. Only one experiment with EGFL8 was 
performed as part of this master thesis. Nevertheless, EGFL8 showed a pronounced effect on STA-
NB-6 cells at a concentration of 100 ng/mL. EGFL8 was recently described to be produced by repair 
type SCs upon injury and in culture [44]. Its low expression was shown as an unfavorable prognostic 
marker for colorectal and gastric cancer, respectively [72, 105]. However, the knowledge on its exact 
function is still very limited, and it has mostly been correlated with EGFL7, which shares similar 
structure and molecular weight in mice [106]. EGFL7 was shown to exhibit its neuritogenic activity on 
neural stem cells by enabling neural differentiation in the brain through inhibition of NOTCH [107]. 
EGFL8 might act in a similar way in the PNS, in promoting cell cycle arrest and axonal outgrowth. 
Since inhibition of NOTCH in NB was shown to induce cell cycle arrest and tumor shrinkage in 
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xenograft mice [108], its potential role in neuronal differentiation via NOTCH should be further 
investigated. 
EGFL8 and PTN could not be directly detected in the SC secretome because their antibodies 
were not included on the arrays used for analysis. Their levels in SC supernatants should be quantified 
by e.g. ELISA assays. Two additional co-cultivation experiments using the STA-NB-6 cell line were 
performed as part of this thesis and their supernatants were stored for future quantification of secreted 
factors, while the cells were FACS-sorted for RNA isolation and the RNA will be further sequenced. 
NGF, BDNF, GDNF, CNTF were not identified by the protein arrays as differentially secreted 
between the co-cultivation/TW experiments and controls, probably because of their very low 
concentrations in cell supernatants. It is known, however, that Schwann cells are a rich source of NGF 
[109], BDNF and CNTF [4, 110], as well as GDNF [111], which is why they were chosen for the 
analysis. Thus, although easy to handle and appropriate for a comprehensive analysis, a limitation of 
the cytokine antibody arrays is low sensitivity.  
Future experiments should investigate receptors and downstream pathways activated by PTN, 
IGFBP6 and EGFL8 in NB cells, resp., e.g. by introducing receptor-blocking antibodies together with 
transcriptomic analysis of cells cultivated in the presence or absence of these factors. Additionally, 
titration experiments are required to determine a possible concentration dependent effect on NB 
differentiation, proliferation and/or apoptosis.  
4.5 SC recruitment plays an important role in tumor maturation 
 
Similar experiments were recently conducted by Pajtler et al. who induced differentiation of 
TrkA-expressing NB cells by addition of SC-conditioned media to cells in culture [112]. However, 
their goal was different. They aimed at identifying key molecules upregulated by NB cells that would 
have the ability of SC attraction, i.e. proliferation and migration [112]. They identified NRG1 and 
furthermore, showed that it induces secretion of NGF by SCs [112], consequently leading to 
neuroblastoma cell differentiation. In agreement with this, substantial upregulation of NGF by SCs 
upon co-cultivation was here presented. This corroborates the hypothesis, that the SCs in favorable 
neuroblastoma, i.e. ganglioneuroma, are reactivated and recruited to the tumor site, where they are 
able to proliferate considerably, explaining their predominance in these tumors [22, 32, 113]. 
The human SC-NB co-cultivation model developed by the Tumor Biology group, CCRI, 
Vienna (manuscript in preparation), might be used in future studies for an in-depth research of these 
pathways with the aim of gaining insight into yet unknown SC-attracting/proliferation inducing 
molecules and exploring the SC-NB cross-talk. 
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4.6 The therapeutic aspect 
 
Despite the extensive research that has been conducted in the last 2 decades, the 5-year overall 
survival rate of high-risk NB patients, that are over 1 year of age and present with metastatic disease, 
is still around 40-50% [18, 114]. Agents intending to induce neuroblastoma differentiation, such as 5-
bromo-2’-deoxyuridine [115], 13-cis-retinoic acid [116] or agents that increase intracellular calcium 
[117] were already tested in clinics. Identification of biologicals and their application in 
neuroblastoma treatment has, however, been hampered by lack of knowledge and challenges in 
delivering growth factors, due to the severe side effects arising with systematic application, as was the 
case with the administration of NGF in numerous disorders [118, 119]. 
One example of a differentiation-inducing protein is PEDF. PEDF was identified in SC 
supernatants and later shown to be present in mature ganglionic cells and SCs in 
ganglioneuroblastomas and ganglioneuromas analyzed by immunostaining [39]. Moreover, 
recombinant PEDF administered in low doses had the ability to induce NB cell differentiation in vivo 
and in vitro, as well as increase the numbers and survival of Schwann cells [39]. Hence, the authors 
suggested that its clinical administration could stimulate a multifaceted antitumor feedback loop with 
the potential to limit tumor growth and indicated that additional SC-derived differentiating agents are 
yet to be discovered [39]. These findings are in line with the results presented in this work, which 
propose PTN, IGFBP6 and EGFL8 as potential anti-neuroblastoma components of the SC secretome. 
The discovered growth-impairing effects of PTN, IGFBP6 and EGFL8 form basis for further in vivo 
experiments. This may contribute to the development of new therapies for aggressive neuroblastoma. 
4.7 An in vivo mouse model for studying SC-NB interaction  
 
A pilot experiment showed that it is feasible to isolate and culture SCs from mouse peripheral 
nerves according to the protocol established for human SCs. Further, they were successfully co-
cultivated in vitro with human STA-NB-6 cells, and mouse SC and NB cell proliferation was 
measured in the co-cultivation experiment. The number of SCs obtained was, however, very low, since 
the small size of mouse peripheral nerves made the isolation challenging. Thus, for future 
experiments, SCs from several animals may be pooled to allow e.g. in vitro co-cultivation 
experiments. Moreover, culture conditions need adaptation. Nevertheless, the pilot experiment shows 
that it would be feasible to establish a NB xenograft model to validate the in vitro findings and test the 
effect of PTN, and other factors, on neuroblastoma growth in vivo. 
Neuroblastoma xenograft models in athymic (nu/nu) mice have so far been used for in vivo 
studies of the SC-NB interaction [112, 120]. Pajtler et al. inoculated a mixture of rat SCs and NB cells, 
suspended in matrigel, subcutaneously (s.c.) in the flank of mice [112]. In this way, they could show 
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that NTRK1 induction in neuroblastoma xenografts mixed with primary SCs significantly reduces 
tumor growth in vivo [112]. On the other hand, Liu et al. injected NB cells intrafascicularly to show 
that mSCs can infiltrate the tumor and promote human neuroblast differentiation, induce apoptosis, as 
well as inhibit proliferation and angiogenesis [120]. 
Xenograft models have also been used to test the effect of SC-secreted factors, such as PEDF 
and SPARC [38, 39]. Crawford et al. treated fully established tumors with recombinant PEDF 
injections s.c. into 3 sites/tumor/day, which they continued for 4 days [39]. They were able to show 
that even a short treatment with recombinant PEDF causes local tumor differentiation [39]. An 
interesting method was used by Chlenski et al., in which purified SPARC was delivered continuously 
for 3 weeks with s.c. implanted osmotic pumps [38]. SPARC was released at a rate of 62.5 ng/h [38]. 
In this manner, they showed complete cessation of tumor growth for the first 2 weeks in SPARC-
treated mice, while, during the third week, a slight increase in tumor size was observed, with the tumor 
volume still being significantly smaller than in control animals [38]. 
Continuous delivery of recombinant protein neuritogens, would be suitable also in the case of 
the newly identified PTN and other factors. According to the in vitro findings in this study, treatment 
should be carried out for at least 17 days and daily doses adjusted to prior dose-response testing. 
Continuous treatment via pumps should be compared with intra-tumoral application to identify the 
optimal way of application. Furthermore, sets of experiments with varying concentrations could be 
conducted 2 or 3 weeks after injection of NB-provoking cells, when the tumor is established, to test 
the effect on tumor growth, in combination with experiments immediately after injection. In this way, 
it could also be tested if PTN has an influence on tumor incidence. 
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5 CONCLUSION 
 
This study identified PTN as a potential factor involved in the Schwann cell-neuroblastoma 
interaction that causes decrease of cell proliferation and increase of cell differentiation when added to 
cell media of STA-NB-6 cells at a concentration of 50 ng/mL for 17 days. NGF was confirmed as a 
neuritogenic factor in STA-NB-6 cells at a concentration of 20 ng/mL. Additionally, IGFBP6 and 
EGFL8 were identified as potential SC-secreted proteins that affect STA-NB-6 cell growth. The 
combination of all factors (PTN, NGF, IGFBP6, EGFL8, BDNF, GDNF, CNTF and FGF7) had no 
significant effect on STA-NB-6 cell proliferation and differentiation. There was no significant effect 
of any of the factors at the tested concentrations on cell proliferation or differentiation on the STA-
NB-10 cell line. 
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6 SUMMARY 
6.1 SUMMARY 
Schwann cells are essential for the maturation process of benign forms of neuroblastoma, 
ganglioneuroma, acting via neuritogenic, anti-proliferative and pro-apoptotic signals. The goal of this 
master thesis was to identify Schwann cell-secreted proteins involved in the cross-talk with 
neuroblastoma cells, and define the concentration and combination needed to induce a growth-
impairing effect in neuroblastoma cells. Eight factors were chosen based on protein array results, 
RNA-sequencing data and literature research: IGFBP6, FGF7, CNTF, PTN, NGF, BDNF, GDNF and 
EGFL8. They were functionally validated in vitro by cultivating two neuroblastoma cell lines derived 
from aggressive tumors, STA-NB-6 and STA-NB-10, in presence of corresponding recombinant 
proteins. The effects were measured by flow cytometry. PTN, IGFBP6 and EGFL8 were identified as 
Schwann cell-secreted proteins that cause reduction of cell proliferation and induction of neuronal-like 
differentiation of STA-NB-6 cells, when individually added to culture media for 17 days. NGF was 
confirmed as a neuritogenic factor of STA-NB-6 cells. The combination of all factors had no 
significant effect on STA-NB-6 cells. The factors had no significant effect on STA-NB-10 cells. This 
work forms basis for further in vitro and in vivo experiments to address the effect of these factors on 
neuroblastoma growth in xenograft models. 
6.2 SAŽETAK 
Schwannove su stanice neophodne za proces sazrijevanja benignih tipova neuroblastoma, 
ganglioneuroma, djelujući kroz neuritogenične, anti-proliferativne i pro-apoptostske signale. Cilj ovog 
diplomskog rada bio je identificirati proteine koje izlučuju Schwanove stanice, a koji sudjeluju u 
njihovoj interakciji sa stanicama neuroblastoma, te definirati koncentraciju i kombinaciju potrebnu za 
inhibiciju rasta stanica neuroblastoma. Usporedbom rezultata dobivenih pomoću analize proteina i 
podataka dobivenih sekvenciranjem transkriptoma s podacima iz literature, izabrano je osam faktora: 
IGFBP6, FGF7, CNTF, PTN, NGF, BDNF, GDNF i EGFL8. Za funkcionalnu potvrdu njihova 
djelovanja in vitro, odgovarajući su rekombinantni proteini dodani u medij korišten za kultiviranje 
dviju staničnih linija neuroblastoma porijeklom iz agresivnih tumora, STA-NB-6 i STA-NB-10, te je 
učinak izmjeren pomoću protočne citometrije. Ovo je istraživanje identificiralo PTN, IGFBP6 i 
EGFL8 kao proteine koje izlučuju Schwannove stanice, koji, kada su individualno dodani staničnom 
mediju tijekom 17 dana, smanjuju proliferaciju i potiču diferencijaciju STA-NB-6 stanica. NGF je 
potvrđen kao neuritogenični faktor STA-NB-6 stanica. Kombinacija svih navedenih faktora nije imala 
značajni učinak na STA-NB-6 stanice. Faktori nisu imali značajan učinak na STA-NB-10 stanice. 
Ovaj rad daje osnovu za daljnja in vitro i buduća istraživanja in vivo, za ispitivanje učinka navedenih 
faktora na rast neuroblastoma metodom staničnog eksplantata. 
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